Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PCRX 
Pacira BioSciences, Inc. (PCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PCRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $29
1 Year Target Price $29
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.69% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.03B USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 6 | Beta 0.41 | 52 Weeks Range 16.00 - 27.64 | Updated Date 10/17/2025 |
52 Weeks Range 16.00 - 27.64 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -18.06% | Operating Margin (TTM) 5.04% |
Management Effectiveness
Return on Assets (TTM) 2.69% | Return on Equity (TTM) -15.57% |
Valuation
Trailing PE - | Forward PE 7.36 | Enterprise Value 1289985282 | Price to Sales(TTM) 1.46 |
Enterprise Value 1289985282 | Price to Sales(TTM) 1.46 | ||
Enterprise Value to Revenue 1.83 | Enterprise Value to EBITDA 4.96 | Shares Outstanding 44932721 | Shares Floating 39823871 |
Shares Outstanding 44932721 | Shares Floating 39823871 | ||
Percent Insiders 1.81 | Percent Institutions 115.3 |
Upturn AI SWOT
Pacira BioSciences, Inc.
Company Overview
History and Background
Pacira BioSciences, Inc. was founded in 2006. It focuses on developing and commercializing novel pharmaceutical products, with a primary focus on non-opioid pain management.
Core Business Areas
- EXPAREL: Non-opioid postsurgical pain management. It is a bupivacaine liposome injectable suspension indicated for single-dose infiltration to produce postsurgical analgesia and as an interscalene brachial plexus nerve block to produce postsurgical analgesia. Its success has made it the primary revenue driver for Pacira.
- ioverau00b0: A handheld cryoanalgesia device used to deliver precise cold therapy to target peripheral nerves, providing immediate pain relief without opioids.
- PharmaEssentia: This is a partnership. Pacira is marketing in the US RUSPERDAu00ae for polycythemia vera
Leadership and Structure
Dave Stack is the Chairman and Chief Executive Officer. The organizational structure includes departments such as Research and Development, Commercial Operations, Finance, and Legal, reporting to executive leadership.
Top Products and Market Share
Key Offerings
- EXPAREL: EXPAREL is Pacira's lead product, a non-opioid postsurgical pain reliever. Revenue from EXPAREL in 2023 was approximately $660 million. Competitors include generic bupivacaine and other pain management therapies, including opioids and nerve blocks using different formulations. Pacira has a significant market share in the non-opioid postsurgical pain management space.
- ioverau00b0: ioverau00b0 is a cryoanalgesia system for pain relief. While specific market share data is less readily available, it's considered a growing segment within pain management devices. Competitors include other cryoanalgesia and nerve ablation technologies from companies like Halyard Health (now Avanos Medical) and Boston Scientific.
- RUSPERDA: RUSPERDA is a prescription medicine used to treat adults with polycythemia vera. This drug is new to Pacira's product portfolio and revenue numbers and market share are still being accumulated. Competitors include other treatment options for polycythemia vera like HUYA BioScience International
Market Dynamics
Industry Overview
The pain management market is large and growing, driven by an aging population and increasing demand for non-opioid alternatives due to concerns about opioid addiction. The market includes pharmaceuticals, devices, and therapies.
Positioning
Pacira BioSciences is positioned as a leader in non-opioid pain management, primarily through EXPAREL. Its competitive advantages include its proprietary liposomal technology and strong clinical data.
Total Addressable Market (TAM)
The global pain management market is expected to reach hundreds of billions of dollars. Pacira is positioned to capture a growing share of this market with its non-opioid alternatives.
Upturn SWOT Analysis
Strengths
- Leading non-opioid pain management product (EXPAREL)
- Proprietary liposomal technology
- Established sales and marketing infrastructure
- Strong clinical data supporting product efficacy
Weaknesses
- Reliance on EXPAREL for revenue
- Potential for generic competition
- High research and development expenses
- Regulatory risk associated with pharmaceutical products
Opportunities
- Expanding indications for EXPAREL
- Acquiring or partnering with other pain management companies
- Developing new non-opioid pain management products
- Expanding into international markets
Threats
- Generic competition for EXPAREL
- Changes in healthcare regulations
- Development of competing non-opioid pain management products
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- BSX
- HCSG
- ITCI
Competitive Landscape
Pacira has a competitive advantage in the non-opioid pain management market due to EXPAREL. However, they face competition from larger pharmaceutical and medical device companies.
Major Acquisitions
Flexion Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 450
- Strategic Rationale: Expanded Pacira's portfolio with Zilretta, an intra-articular steroid injection for osteoarthritis knee pain.
Growth Trajectory and Initiatives
Historical Growth: Pacira has experienced significant growth, driven by EXPAREL adoption and acquisitions.
Future Projections: Analysts project continued revenue growth, driven by EXPAREL expansion and new product launches.
Recent Initiatives: Recent initiatives include expanding the indications for EXPAREL, strategic partnerships, and potential acquisitions.
Summary
Pacira BioSciences is a leader in non-opioid pain management, primarily due to the success of EXPAREL. The company is growing through product expansion and strategic acquisitions. Future challenges include potential generic competition and the need to continue innovating. Pacira's focus on alternatives to opioids positions it well in the current healthcare environment. However, they must continue to diversify their product line to mitigate risks related to reliance on EXPAREL.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Company website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacira BioSciences, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2011-02-03 | CEO & Director Mr. Frank D. Lee | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 788 | Website https://www.pacira.com |
Full time employees 788 | Website https://www.pacira.com | ||
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.